Navigation Links
Novel Anti-Inflammatories May Offer a New Approach for the Treatment of Stroke
Date:6/25/2012

Los Angeles, California (PRWEB) June 25, 2012

New evidence supporting the potential value of a new type of anti-inflammatory treatment for stroke published last week in the Journal of Cerebral Blood Flow & Metabolism[1]. The new animal study documented more than 40% reduction in stroke size(volume) and neural deficit after treatment with a new TNF-alpha decoy receptor fusion protein, a class of drugs originally developed to treat forms of arthritis. This new study is the latest in a series of animal experiments that goes back more than a decade and follows publication last year of the first human results of the use of a TNF-alpha decoy receptor fusion protein following stroke[2]. The human study, performed at the Institute of Neurological Recovery (INR) in Los Angeles, documented rapid and sustained improvement following treatment at the INR. News reports (see below) have documented the striking potential of the revolutionary new INR treatment approach.

Scientific Background

Stroke produces tissue damage in the brain that causes a detrimental inflammatory response and elevation of the levels of a protein, TNF, that amplifies inflammation. TNF-alpha decoy receptor fusion proteins, such as etanercept, and other biologic TNF inhibitors reduce the damage caused by excess levels of TNF. These new stroke studies suggest that TNF-alpha decoy receptor fusion proteins may have the potential to improve brain function, if administered in ways that allow brain penetration. The INR in Los Angeles and Boca Raton, Florida has pioneered patented [3] anti-TNF methods for treatment of neuroinflammatory disorders, including stroke, Alzheimer's disease, and sciatica. Rapid clinical improvement in brain function in AD following the use of a TNF-alpha decoy receptor fusion protein has been documented on 60 Minutes in Australia in their feature entitled "A New Shot at Life" and in the scientific literature[4].

For further information, please see the website of the Institute of Neurological Recovery: http://www.strokebreakthrough.com

References
1. Sumbria, R.K., et al., Brain protection from stroke with intravenous TNFalpha decoy receptor-Trojan horse fusion protein. J Cereb Blood Flow Metab, 2012.
2. Tobinick, E., Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs, 2011. 25(2): p. 145-55.
3. Issued and pending U.S. and international patents, including, but not limited to U.S. patents 6,982,089; 7,629,311; 7,214,658; and 8,119,127, all assigned to TACT IP, LLC and Australian patent 758,523.
4. For further scientific references please see the INR website Scientific Publications webpage.

© 2012 Institute of Neurological Recovery (INR®)

Read the full story at http://www.prweb.com/releases/2012/6/prweb9633325.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
2. Rutgers team discovers novel approach to stimulate immune cells
3. Novel drug candidates offer new route to controlling inflammation
4. Researchers present new findings for novel pancreatic cancer vaccine
5. Novel biomarkers reveal evidence of radiation exposure
6. VCU Massey Cancer Center sees potential in novel leukemia treatment
7. Study supports urate protection against Parkinsons disease, hints at novel mechanism
8. Novel Natural Sciences Repository Opens Web Portal
9. Experts Offer Advice After Yankee Pitchers Trampoline Injury
10. Mayo Clinic offers newly approved treatment for acid reflux disease
11. Here Are Fruits, Veggies That Offer Best Bang for Your Buck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology: